微管相关蛋白2在胰腺神经内分泌肿瘤组织中的表达及预后意义

摘要

Objective: To determine whether microtubule-associated protein 2 (MAP2) and microtubule-associated protein 1B (MAP1B) could be prognostic biomarkers for patients with pancreatic neuroendocrine tumors (PNETs). Methods:With immunohisto-chemical staining, the expressions of MAP2 and MAP1B were examined in 193 and 120 primary tumors and peritumoral tissues, re-spectively. Then, the relationship between the expression of each protein and clinicopathological characteristics, including prognosis was analyzed. Results:MAP2 and MAP1B were expressed in 88 of 193 (45.6%) and 77 of 120 (64.2%) tumors, respectively. The expres-sion of MAP2 was significantly associated with the favorable overall survival of patients with PNETs (P=0.012). Moreover, MAP2 expres-sion was associated with the improved overall survival in a subset of patients with stageⅡand stageⅢtumors (P=0.017). The MAP1B expression did not correlate with other clinicopathological features and prognosis. Conclusion:MAP2 could be a novel, independent prognostcbiomarker for PNETs.%目的:探索微管相关蛋白2(microtubule-associated protein 2,MAP2)与微管相关蛋白1B(microtubule-associated protein 1B,MAP1B)在预测胰腺神经内分泌肿瘤(pancreatic neuroendocrine tumors,PNETs)患者预后中的意义.方法:收集1999年12月至2016年12月来自于北京协和医院、中山大学附属第一医院、复旦大学上海癌症中心和Cedars-Sinai医学中心(洛杉矶)193例患者的193个原发肿瘤标本.免疫组织化学染色法分别检测193例、120例PNETs组织中MAP2、MAP1B的表达,随后分析蛋白表达与患者临床病理特征及预后的关系.结果:MAP2和MAP1B在PNETs患者中的阳性率分别为45.6%(88/193)和64.2%(77/120).MAP2表达阳性的患者的总生存好于阴性患者(P=0.012).另外,MAP2阳性Ⅱ、Ⅲ期患者的总生存也优于阴性者(P=0.017).然而,MAP1B的表达与肿瘤大小、转移、肿瘤组织学分级、临床分期、总生存、无病生存均无相关性(P>0.05).结论:MAP2为潜在的预测PNETs患者预后的指标.